ArticleTherapeutic advances in gastroenterology2023

Discontinuation of infliximab treatment in patients with inflammatory bowel disease who retransitioned to originator and those who remained on biosimilar.

Rosanne W Meijboom et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.